LivingGLP1
Study S002451

A Phase1 Study to Characterize Mass Balance Of [14C] HDM1002 in Chinese Healthy Subjects

ClinicalTrials.gov record

Registration

Registration
NCT06576401
Study type
INTERVENTIONAL
Phase
PHASE1
Masking
NONE
Status
UNKNOWN
Enrollment
10
Start
2024-08-27
Primary completion
2024-10
Lead sponsor
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Conditions
Healthy Adult Subject
Interventions
DRUG:[14C] HDM1002
Results posted
FALSE

Registered primary outcomes

  • Total recovery of HDM1002 radioactivity in urine and feces, following oral administration of [14C] HDM1002 [Predose up to Day 11 after administration of [14C] HDM1002]
  • Metabolite profiling/identification in plasma, urine, and feces [Predose up to Day 11 after administration of [14C] HDM1002]
  • Plasma and whole blood AUC[0-t] of radioactivity [Predose up to Day 11 after administration of [14C] HDM1002]
  • Plasma and whole blood AUC[0-∞] of radioactivity [Predose up to Day 11 after administration of [14C] HDM1002]
  • Plasma and whole blood Cmax of radioactivity [Predose up to Day 11 after administration of [14C] HDM1002]
  • Plasma and whole blood Tmax of radioactivity [Predose up to Day 11 after administration of [14C] HDM1002]
  • Plasma and whole blood t1/2 of radioactivity [Predose up to Day 11 after administration of [14C] HDM1002]
  • Plasma and whole blood CL/F of radioactivity [Predose up to Day 11 after administration of [14C] HDM1002]
  • Plasma and whole blood Vz/F of radioactivity [Predose up to Day 11 after administration of [14C] HDM1002]
  • Percentage of plasma HDM1002 and metabolites in total plasma radioactivity [Predose up to Day 11 after administration of [14C] HDM1002]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.